Know Cancer

or
forgot password

A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma


Phase 1
18 Years
N/A
Open (Enrolling)
Both
Metastatic Cancer, Melanoma

Thank you

Trial Information

A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma


Background:

Adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) can mediate the
regression of bulky metastatic melanoma when administered to the autologous patient along
with high-dose aldesleukin (IL-2) following a non-myeloablative lymphodepleting chemotherapy
preparative regimen.

Vemurafenib (VEM) administration has been shown to mediate objective responses in 50-60
percent of patients with metastatic melanoma bearing a BRAF mutation though many of these
responses are transient.

There are several reasons to suggest that the combination of ACT with VEM will synergize in
the destruction of melanoma including 1) rapid tumor destruction by VEM may provide a
vaccine-like stimulus to the transferred TIL; 2) VEM has been shown to upregulate the
expression of melanoma antigens; 3)VEM may make residual melanoma cells more sensitive to
immune damage.

Objectives:

The primary objective is to determine the safety of the administration of vemurafenib in
conjunction with ACT consisting of autologous TIL infused along with high dose aldesleukin
following a non-myeloablative lymphodepleting preparative regimen.

The secondary objectives are:

- To gain preliminary information concerning the ability of the combination therapy to
mediate clinical tumor regression in patients with metastatic melanoma.

- To study the immunologic impact of VEM administration on the lymphoid infiltrate in
melanoma deposits.

Eligibility:

Patients greater than or equal to 18 years old with pathologically confirmed diagnosis of

metastatic melanoma that expresses the V to E BRAF mutation.

Patients with measurable disease, absolute neutrophil count greater than 1000/mm(3) and
platelet count greater than 100,000/mm(3).

No serious comorbid conditions such as active systemic infections, coagulation disorders, or
other active major medical illnesses of the cardiovascular, respiratory or immune systems.

Design:

Patients will undergo biopsy or resection to obtain tumor for generation of autologous TIL
cultures.

When cryopreserved TIL are available patients will begin the administration of VEM 960 mg
(day 1) twice daily until disease progression or patients are taken off protocol.

On day -7, patients will begin a non-myeloablative lymphocyte depleting preparative regimen
of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day IV) on
days -5 through -1.

On day 0, patients will receive between 1x109 to 2x1011 young TIL and then begin high dose
aldesleukin (720,000 IU/kg IV every 8 hours for up to 15 doses).

Clinical and immunologic responses will be evaluated about 4-6 weeks after the last dose of
aldesleukin.

This pilot trial will accrue 25 patients.

Inclusion Criteria


-INCLUSION CRITERIA:

1. Measurable metastatic melanoma that expresses the VtoE BRAF mutation assessed in a
CLIA certified laboratory.

2. Patients with 3 or less brain metastases are eligible. Note: If lesions are
symptomatic or greater than or equal to 1 cm each, these lesions must have been
treated and stable for 3 months for the patient to be eligible.

3. Greater than or equal to 18 years of age.

4. Willing to practice birth control during treatment and for four months after
receiving all protocol related therapy.

5. Life expectancy of greater than three months

6. Willing to sign a durable power of attorney.

7. Able to understand and sign the Informed Consent Document

8. Clinical performance status of ECOG 0 or 1.

9. Hematology:

- Absolute neutrophil count greater than 1000/mm(3)

- Hemoglobin greater than 8.0 g/dl

- Platelet count greater than 100,000/mm(3)

10. Serology:

- Seronegative for HIV antibody. (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who are HIV
seropositive can have decreased immune competence and thus be less responsive to
the experimental treatment and more susceptible to its toxicities.)

- Seronegative for hepatitis B antigen, or hepatitis C antibody or antigen.

11. Chemistry:

- Serum ALT/AST less than three times the upper limit of normal.

- Calculated creatinine clearance (eGFR) > 50 ml/min.

- Total bilirubin less than or equal to 2 mg/dl, except in patients with Gilbert's
Syndrome who must have a total bilirubin less than 3 mg/dl.

12. More than four weeks must have elapsed since any prior systemic therapy at the time
of treatment, and patients' toxicities must have recovered to a grade 1 or less
(except for alopecia or vitiligo). Patients must have stable or progressing disease
after prior treatment.

Note: Patients may have undergone minor surgical procedures within the past 3 weeks,
as long as all toxicities have recovered to grade 1 or less or as specified in the
eligibility criteria in Section 2.1.1.

13. Six weeks must have elapsed since any prior anti-CTLA4 antibody therapy to allow
antibody levels to decline.

14. Patients who have previously received any anti-CTLA4 antibody and have documented GI
toxicity must have a normal colonoscopy with normal colonic biopsies.

15. EKG with mean QTc interval < 450 msec.

EXCLUSION CRITERIA:

1. Prior cell transfer therapy which included a myeloablative chemotherapy regimen (i.e.
1200 TBI or 200 TBI plus chemotherapy).

2. Previous treatment with Vemurafenib.

3. Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

4. Systemic steroid therapy requirement.

5. Active systemic infections, coagulation disorders or other active major medical
illnesses of the cardiovascular, respiratory or immune system, as evidenced by a
positive stress thallium or comparable test, myocardial infarction, cardiac
arrhythmias, obstructive or restrictive pulmonary disease.

6. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease and AIDS).

7. Opportunistic infections (The experimental treatment being evaluated in this protocol
depends on an intact immune system. Patients who have decreased immune competence may
be less responsive to the experimental treatment and more susceptible to its
toxicities.)

8. History of severe immediate hypersensitivity reaction to any of the agents used in
this study.

9. History of coronary revascularization or ischemic symptoms.

10. Any patient known to have an LVEF less than or equal to 45 percent.

11. In patients > 60 years old, documented LVEF of less than or equal to 45 percent.

12. Documented FEV1 less than or equal to 60 percent predicted tested in patients with:

- A prolonged history of cigarette smoking

- Symptoms of respiratory dysfunction

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine the safety of the administration of vemurafenib in conjunction with ACT consisting of autologous TIL infused along with high dose aldesleukin following a non-myeloablative lymphodepleting preparative regimen.

Principal Investigator

Steven A Rosenberg, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

120114

NCT ID:

NCT01585415

Start Date:

April 2012

Completion Date:

May 2014

Related Keywords:

  • Metastatic Cancer
  • Melanoma
  • Immunotherapy
  • Adoptive Cell Therapy
  • B Raf Inhibitor
  • Melanoma
  • Neoplasm Metastasis
  • Neoplasms
  • Neoplasms, Second Primary

Name

Location

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892